James George Chopas Sells 715 Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Stock

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) CAO James George Chopas sold 715 shares of the stock in a transaction on Friday, January 17th. The shares were sold at an average price of $29.96, for a total value of $21,421.40. Following the completion of the transaction, the chief accounting officer now directly owns 36,643 shares in the company, valued at approximately $1,097,824.28. This trade represents a 1.91 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

James George Chopas also recently made the following trade(s):

• On Monday, January 13th, James George Chopas sold 783 shares of Apellis Pharmaceuticals stock. The shares were sold at an average price of $28.70, for a total value of $22,472.10.

Apellis Pharmaceuticals Stock Up 0.6 %

Apellis Pharmaceuticals stock traded up $0.19 during mid-day trading on Tuesday, reaching $30.13. The company’s stock had a trading volume of 1,461,289 shares, compared to its average volume of 2,274,031. The company has a debt-to-equity ratio of 1.91, a quick ratio of 3.73 and a current ratio of 4.36. Apellis Pharmaceuticals, Inc. has a 12 month low of $24.34 and a 12 month high of $71.90. The business’s 50 day simple moving average is $31.89 and its 200 day simple moving average is $33.31. The company has a market capitalization of $3.75 billion, a price-to-earnings ratio of -14.84 and a beta of 0.94.

Apellis Pharmaceuticals (NASDAQ:APLS) last announced its quarterly earnings data on Tuesday, November 5th. The company reported ($0.46) earnings per share for the quarter, missing the consensus estimate of ($0.32) by ($0.14). Apellis Pharmaceuticals had a negative net margin of 34.97% and a negative return on equity of 103.11%. The company had revenue of $196.83 million during the quarter, compared to the consensus estimate of $200.00 million. During the same quarter in the previous year, the business earned ($1.17) EPS. Apellis Pharmaceuticals’s revenue was up 78.3% on a year-over-year basis. As a group, research analysts anticipate that Apellis Pharmaceuticals, Inc. will post -1.71 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in APLS. Merit Financial Group LLC acquired a new stake in shares of Apellis Pharmaceuticals in the 4th quarter valued at approximately $254,000. Hennion & Walsh Asset Management Inc. increased its holdings in Apellis Pharmaceuticals by 135.6% during the fourth quarter. Hennion & Walsh Asset Management Inc. now owns 29,740 shares of the company’s stock worth $949,000 after buying an additional 17,115 shares during the last quarter. Eastern Bank raised its position in Apellis Pharmaceuticals by 87.0% during the fourth quarter. Eastern Bank now owns 21,500 shares of the company’s stock worth $686,000 after acquiring an additional 10,000 shares in the last quarter. JPMorgan Chase & Co. lifted its stake in Apellis Pharmaceuticals by 23.3% in the third quarter. JPMorgan Chase & Co. now owns 3,884,730 shares of the company’s stock valued at $112,036,000 after acquiring an additional 735,160 shares during the last quarter. Finally, Exome Asset Management LLC lifted its stake in Apellis Pharmaceuticals by 114.0% in the third quarter. Exome Asset Management LLC now owns 100,367 shares of the company’s stock valued at $2,895,000 after acquiring an additional 53,467 shares during the last quarter. Institutional investors and hedge funds own 96.29% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts have recently commented on APLS shares. Morgan Stanley began coverage on Apellis Pharmaceuticals in a research note on Thursday, November 21st. They issued an “equal weight” rating and a $31.00 price target for the company. Mizuho lowered their target price on shares of Apellis Pharmaceuticals from $39.00 to $38.00 and set a “neutral” rating for the company in a research note on Thursday, October 24th. Piper Sandler reduced their price target on shares of Apellis Pharmaceuticals from $40.00 to $32.00 and set a “neutral” rating on the stock in a research report on Wednesday, November 6th. Oppenheimer reduced their target price on Apellis Pharmaceuticals from $65.00 to $40.00 and set an “outperform” rating on the stock in a report on Wednesday, November 6th. Finally, Needham & Company LLC lowered their price target on Apellis Pharmaceuticals from $85.00 to $60.00 and set a “buy” rating for the company in a report on Wednesday, November 6th. Eight analysts have rated the stock with a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $46.71.

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).